337917-94-9

Upstream product

• 1160184-14-4 2,6-dibromo-4-iodopyridine 
• 98-80-6 phenylboronic acid 
• 98027-81-7 2,6-dibromo-4-nitro-pyridine 1-oxide 
• 25373-69-7 2,6-dibromopyridin N-oxide 
• 626-05-1 2,6-Dibromopyridine 
• 39771-34-1 4-amino-2,6-dibromopyridine 
• 71-43-2 benzene 

Downstream Products

• 1291081-25-8 2-bromo-4,6-diphenylpyridine 
• 128736-34-5 2-bromo-6-(methylthio)-4-phenylpyridine 
• 337917-98-3 tetraethyl N,N,N',N'-[2,6-bis(3'-bromomethyl-1'-pyrazolyl)-4-phenylpyridine] tetrakis acetate 
• 337917-99-4 N,N,N',N'-[2,6-bis(3'-bromomethyl-1'-pyrazolyl)-4-phenylpyridine] tetrakis(acetic acid) 
• 337917-96-1 2,6-bis(3'-hydroxymethyl-1'-pyrazolyl)-4-phenylpyridine 
• 337917-97-2 2,6-bis(3'-bromomethyl-1'-pyrazolyl)-4-phenylpyridine 
• 337917-95-0 2,6-bis(3'-methoxycarbonyl-1'-pyrazolyl)-4-phenylpyridine 

Relevant academic research and scientific papers

TYK-2 INHIBITOR

Disclosed herein is a compound of Formula (I) for inhibiting TYK2 and treating a disease associated with the undesirable tyk-2 activity (tyk-2 related diseases), a method of using the compounds disclosed herein for treating inflammatory or autoimmune disease, and a pharmaceutical composition comprising the same.

Condensed-cyclic compound and organic light emitting device comprising the same

Disclosed are a condensed ring compound represented by chemical formula 1, and an organic light emitting device comprising the same. The organic light emitting device comprising the condensed cyclic compound may have low driving voltage, high efficiency, high luminance, and long lifespan properties.COPYRIGHT KIPO 2017

Heteroanthracene pyrene compounds and OLED (organic light emitting diode) based on same

The invention provides heteroanthracene pyrene compounds and an OLED (organic light emitting diode) based on the same, and belongs to the technical field of organic photoelectric materials. The technical problems that the organic photoelectric materials have poor light emitting properties such as low light emitting efficiency, higher driving voltage, short service life and the like in the prior art are solved. Compared with the prior art, the OLED based on the heteroanthracene pyrene compounds has the advantages that light emitting properties are improved, and the compounds are excellent OLED materials.

PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase and/or Janus kinases.

Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase and/or Janus kinases.

Synthesis of a terbium fluorescent chelate and its application to time-resolved fluoroimmunoassay

A new nonadentate ligand, N, N, Nl, N1-[2,6-bis(3′aminomethyl-1′-pyrazolyl)-4- phenylpyridine]tetrakis(acetic acid) (BPTA) for a Tb3+ fluorescent complex was synthesized. The Tb3+ complex is strongly fluorescent, having a large fluorescence quantum yield of 1.00 and very long fluorescence lifetime of 2.681 ms in 0.05 M borate buffer of pH 9.1. Streptavidin (SA) was labeled with BPTA by using its succinimidyl monoester, and the BPTA-Tb3+-labeled SA was used in sandwich-type time-resolved fluoroimmunoassay (TR-FIA) of α-fetoprotein (AFP) and carcinoembryonic antigen (CEA) in human sera. The Tb3+-labeled SA was also used in competitive-type TR-FIA of bensulfuron-methyl (BSM) in water. The detection limits of these assays are 42 pg/mL for AFP, 70 pg/mL for CEA, and 0.4 ng/mL for BSM. In addition, a new simultaneous measurement method for AFP and CEA in a human serum sample was developed by using 4,4′-bis(l″,1″,1″,2″,2″,3″,3″ -heptafluoro-4″,6″-hexanedion-6″-yl)chlorosulfo-o-terphenyl (BHHCT)-Eu3+-labeled anti-AFP antibody, biotinylated anti-CEA antibody, and BPTA-Tb3+-labeled SA. The concentrations of AFP and CEA in 39 human serum samples were determined, and the results were compared with those of the independently determined AFP and CEA by TR-FIA with a single-label method. A good correlation was obtained with the correlation coefficients of 0.991 for AFP and 0.994 for CEA.